A Nature Communications analysis dissected germline and somatic variation in complement system genes and linked them to pancreatic cancer risk, tumor microenvironment changes, and patient prognosis. The study used multi‑omic datasets to show that complement pathway alterations reshape immune infiltration and correlate with survival. Authors propose complement gene signatures could stratify patients for complement-targeted therapies or immunomodulatory combinations. The paper provides candidate biomarkers and mechanistic hypotheses to inform early-phase clinical trials in a cancer type with limited therapeutic options.